Trastuzumab deruxtecan (T-DXd) + Pertuzumab FDA Approval in Adv HER2 Breast Cancer: DESTINY-Breast09

In this episode of the Oncology Brothers podcast, we dived deep into the recent FDA approval of T-DXd (trastuzumab deruxtecan) plus Pertuzumab for the treatment of HER2-positive metastatic breast cancer. Joined by Dr. Sara Tolaney, the lead author of the DESTINY-Breast 09 study, where we discussed the findings that show a significant improvement in progression-free survival (PFS) from 26.9 months to 40.7 months, with a hazard ratio of 0.56.

Key topics included:
• The design and findings of the DESTINY-Breast09 trial
• Comparison with traditional treatment regimen THP (trastuzumab, pertuzumab, and taxane)
• The implications of these findings for clinical practice
• The role of maintenance therapy and the potential for personalized treatment strategies
• Common side effects associated with T-DXd and pertuzumab, including ILD (Interstitial Lung Disease)

Join us as we explore the future of HER2-positive breast cancer treatment and the exciting developments that are changing the landscape for patients.

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers
•⁠  Website: https://oncbrothers.com/

 Don't forget to subscribe for more insights on treatment algorithms, FDA approvals, and conference highlights!

#HER2positiveBreastCancer, #TrastuzumabDeruxtecan, #DestinyBreast09, #MetastaticBreastCancer, #OncologyBrothers